Crown Bioscience, Inc. Expands Its Presence In France With Severine Marrony, Ph.D.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Crown Bioscience, a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research, is pleased to announce that Severine Marrony, Ph.D., has joined Crown Bioscience as manager, business development, in France.

"Her business development and technical expertise will support our rapid expansion in France."

Marrony has held various business development roles for global life science companies and brings a wealth of knowledge in the areas of microbiology, pharmacology, toxicology, molecular and cellular biology, and immunology. She has a Ph.D. in molecular and cellular biology, and immunology from Strasbourg University and was involved in two patents while working at Novartis. She is fluent in French, English and German.

"We are thrilled to have Severine join the Crown team," said Laurie Heilmann, senior vice president of global strategy, marketing and business development at Crown Bioscience. "Her business development and technical expertise will support our rapid expansion in France."

In addition, Crown Bioscience's application to the French Ministry of National Education, Higher Education and Research to conduct research and development (R&D) for companies in France for the years 2015, 2016 and 2017 has been approved.

The approval has a material impact on Crown Bioscience clients. They will now be able to declare purchased service amounts to be eligible for R&D tax credit (CIR) in accordance with article 244 section B of the general tax code, section 49 F and 49 M of the annex. Crown Bioscience estimates that these tax credits will effectively decrease the net cost of these R&D services by approximately 30 percent.

About Crown Bioscience Inc.

Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

For more information, please visit www.crownbio.com.

Contacts

For Crown Bioscience:
SCORR Marketing
Lea Studer, +1 308-237-5567
[email protected]

Suggested Articles

Notable Labs is adding $40 million to its reserves as it scales up its capabilities with plans to take its platform worldwide.

Trefoil Therapeutics raised $28 million to push its regenerative treatment for corneal dystrophies toward the clinic.

The financing sets AM-Pharma up to advance in sepsis-associated acute kidney injury independently now Pfizer has turned down its option to buy.